Temporal patterns of childhood cancer survival 1991 to 2016: A nationwide register-study based on data from the German Childhood Cancer Registry.
Childhood cancer
German Childhood Cancer Registry
Survival analysis
Temporal survival patterns
Journal
International journal of cancer
ISSN: 1097-0215
Titre abrégé: Int J Cancer
Pays: United States
ID NLM: 0042124
Informations de publication
Date de publication:
15 08 2023
15 08 2023
Historique:
revised:
12
04
2023
received:
04
02
2023
accepted:
19
04
2023
medline:
21
6
2023
pubmed:
9
5
2023
entrez:
9
5
2023
Statut:
ppublish
Résumé
Childhood cancer is the leading disease-related cause of death among under 15 year olds in Europe. Since primary preventive measures are lacking, improving survival probabilities and long-term well-being remain primary goals. With this report, we provide the first long-term assessment and interpretation of patterns in childhood cancer survival in Germany, covering a period of 30 years. Using data from the German Childhood Cancer Registry, we assessed temporal patterns of cancer survival among children (0-14 years) diagnosed in Germany from 1991 to 2016, by cancer type, age at diagnosis and sex. We calculated overall survival (OS) and average annual percentage changes of the respective 5-year OS estimates. OS improved across all cancer types, age groups as well as for boys and girls over time. Five-year OS for all childhood cancers combined increased from 77.8% in 1991-1995 to 86.5% in 2011-2016, with stronger improvements during the early 1990s. The most pronounced survival improvement was seen for acute myeloid leukaemia, at 2% annually and 5-year OS recently reaching 81.5%. Survival improvements for some diagnoses such as neuroblastoma, renal tumours and bone tumours have flattened out. Tremendous enhancements in diagnostics, treatment and supportive care have affected average survival improvements for most cancer types. Recently, survival improvements have decelerated overall and for some cancer types, it plateaued at an unsatisfactory level. As not all children benefited equally from the survival improvements, personal factors (eg, socioeconomic circumstances, health literacy, access to care) likely affect individual prognosis and warrant further investigation.
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
742-755Informations de copyright
© 2023 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC.
Références
Steliarova-Foucher E, Colombet M, Ries LAG, et al. International incidence of childhood cancer, 2001-10: a population-based registry study. Lancet Oncol. 2017;18:719-731.
Janßen G, Kuhlen M. Kinder und Jugendliche mit lebensverkürzenden Erkrankungen/in der palliativen Versorgung. In: Schnell MW, Schulz C, eds. Basiswissen Palliativmedizin. Berlin, Heidelberg: Springer Berlin Heidelberg; 2012:301-310.
Wolfe I, Thompson M, Gill P, et al. Health services for children in western Europe. Lancet. 2013;381:1224-1234.
Steliarova-Foucher E, Fidler MM, Colombet M, et al. Changing geographical patterns and trends in cancer incidence in children and adolescents in Europe, 1991-2010 (Automated Childhood Cancer Information System): a population-based study. Lancet Oncol. 2018;19:1159-1169.
Erdmann F, Kaatsch P, Grabow D, Spix C. Annual Report 2019 (1980-2018), vol. 2021: Institute of Medical Biostatistics, Epidemiology and Informatics at the University Medcal Center of the Johannes Gutenberg University Mainz. 2020.
Frederiksen LE, Erdmann F, Mader L, et al. Psychiatric disorders in childhood cancer survivors in Denmark, Finland, and Sweden: a register-based cohort study from the SALiCCS research programme. Lancet Psychiatry. 2022;9:35-45.
Frederiksen LE, Pedersen C, Mogensen H, et al. Employment status and occupational positions of childhood cancer survivors from Denmark, Finland and Sweden: a Nordic register-based cohort study from the SALiCCS research programme. Lancet Reg Health Eur. 2022;12:100258.
Erdmann F, Frederiksen LE, Bonaventure A, et al. Childhood cancer: survival, treatment modalities, late effects and improvements over time. Cancer Epidemiol. 2021;71:101733.
Frederiksen LE, Mader L, Feychting M, et al. Surviving childhood cancer: a systematic review of studies on risk and determinants of adverse socioeconomic outcomes. Int J Cancer. 2019;144:1796-1823.
Steliarova-Foucher E, Colombet M, Ries L, et al. International Incidence of Childhood Cancer, Volume III (electronic version). Lyon, France: IARC; 2017.
Wellbrock M, Spix C, Grabow D, Erdmann F. Epidemiologie von Krebserkrankungen im Kindes- und Jugendalter. Der Onkologe. 2021;27:401-409.
Spector LG, Pankratz N, Marcotte EL. Genetic and nongenetic risk factors for childhood cancer. Pediatr Clin North Am. 2015;62:11-25.
Erdmann F, Ghantous A, Schüz J. Environmental agents and childhood cancer. In: Nriagu J, ed. Encyclopedia of Environmental Health. Vol 2. Elsevier B.V; 2019:347-359.
Schüz J, Erdmann F. Environmental exposure and risk of childhood leukemia: an overview. Arch Med Res. 2016;47:607-614.
Stanulla M, Erdmann F, Kratz CP. Risikofaktoren für Krebserkrankungen im Kindes- und Jugendalter. Monatsschr Kinderheilkd. 2020;169:30-38.
Rossig C, Juergens H, Schrappe M, et al. Effective childhood cancer treatment: the impact of large scale clinical trials in Germany and Austria. Pediatr Blood Cancer. 2013;60:1574-1581.
Smith MA, Reaman GH. Remaining challenges in childhood cancer and newer targeted therapeutics. Pediatr Clin North Am. 2015;62:301-312.
World Health Organization. Regional office for Europe. In: Office for Prevention & Control of NCDs, ed. Childhood Cancer Inequalities in the WHO European Region. Copenhagen: World Health Organization, Regional Office for Europe; 2022.
Gatta G, Botta L, Rossi S, et al. Childhood cancer survival in Europe 1999-2007: results of EUROCARE-5-a population-based study. Lancet Oncol. 2014;15:35-47.
Bertuccio P, Alicandro G, Malvezzi M, et al. Childhood cancer mortality trends in Europe, 1990-2017, with focus on geographic differences. Cancer Epidemiol. 2020;67:101768.
Bhatia S. Disparities in cancer outcomes: lessons learned from children with cancer. Pediatr Blood Cancer. 2011;56:994-1002.
Schindler M, Belle FN, Grotzer MA, von der Weid NX, Kuehni CE. Childhood cancer survival in Switzerland (1976-2013): time-trends and predictors. Int J Cancer. 2017;140:62-74.
Botta L, Gatta G, Capocaccia R, et al. Long-term survival and cure fraction estimates for childhood cancer in Europe (EUROCARE-6): results from a population-based study. Lancet Oncol. 2022;23:1525-1536.
United Nations. Human Development Report 2021-22. UNDP (United Nations Development Programme). 2022.
Basta NO, James PW, Gomez-Pozo B, Craft AW, McNally RJ. Survival from childhood cancer in northern England, 1968-2005. Br J Cancer. 2011;105:1402-1408.
Madanat-Harjuoja LM, Pokhrel A, Kivivuori SM, Saarinen-Pihkala UM. Childhood cancer survival in Finland (1953-2010): a nation-wide population-based study. Int J Cancer. 2014;135:2129-2134.
Steliarova-Foucher E, Stiller C, Lacour B, Kaatsch P. International classification of childhood cancer, third edition. Cancer. 2005;103:1457-1467.
Katz D, Baptista J, Azen SP, Pike MC. Obtaining confidence intervals for the risk ratio in cohort studies. Biometrics. 1978;34:469-474.
Tunes da Silva G, Logan BR, Klein JP. Methods for equivalence and noninferiority testing. Biol Blood Marrow Transplant. 2009;15:120-127.
Methodology S, Branch A. Joinpoint Regression Program, Version 4.9.0.1: Surveillance Research Program. Bethesda: National Cancer Institute; 2022.
SAS Institute Inc. SAS® Software 9.4. Cary: SAS Institute; 2016.
Simone JV. History of the treatment of childhood ALL: a paradigm for cancer cure. Best Pract Res Clin Haematol. 2006;19:353-359.
Erdmann F, Frederiksen LE, Bonaventure A, et al. Childhood cancer: survival, treatment modalities, late effects and improvements over time. Cancer Epidemiol. 2020;2020:101733.
Schrappe M, Möricke A, Reiter A, et al. Key treatment questions in childhood acute lymphoblastic leukemia: results in 5 consecutive trials performed by the ALL-BFM study group from 1981 to 2000. Klin Padiatr. 2013;225(Suppl 1):S62-S72.
Schramm F, Zur Stadt U, Zimmermann M, et al. Results of CoALL 07-03 study childhood ALL based on combined risk assessment by in vivo and in vitro pharmacosensitivity. Blood Adv. 2019;3:3688-3699.
Möricke A, Reiter A, Zimmermann M, et al. Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95. Blood. 2008;111:4477-4489.
Society of Pediatric Oncology and Hematology (GPOH). Studien Und Register der GPOH-Onkologie. Vol 2022. Berlin: GPOH; 2022.
Attarbaschi A, Mann G, Zimmermann M, et al. Randomized post-induction and delayed intensification therapy in high-risk pediatric acute lymphoblastic leukemia: long-term results of the international AIEOP-BFM ALL 2000 trial. Leukemia. 2020;34:1694-1700.
Creutzig U, Zimmermann M, Dworzak MN, Ritter J, Schellong G, Reinhardt D. Development of a curative treatment within the AML-BFM studies. Klin Padiatr. 2013;225:S79-S86.
Rasche M, Zimmermann M, Borschel L, et al. Successes and challenges in the treatment of pediatric acute myeloid leukemia: a retrospective analysis of the AML-BFM trials from 1987 to 2012. Leukemia. 2018;32:2167-2177.
Sander A, Zimmermann M, Dworzak M, et al. Consequent and intensified relapse therapy improved survival in pediatric AML: results of relapse treatment in 379 patients of three consecutive AML-BFM trials. Leukemia. 2010;24:1422-1428.
Sauer MG, Lang PJ, Albert MH, et al. Hematopoietic stem cell transplantation for children with acute myeloid leukemia-results of the AML SCT-BFM 2007 trial. Leukemia. 2020;34:613-624.
Woessmann W, Seidemann K, Mann G, et al. The impact of the methotrexate administration schedule and dose in the treatment of children and adolescents with B-cell neoplasms: a report of the BFM Group Study NHL-BFM95. Blood. 2005;105:948-958.
Frühwald MC, Rutkowski S. Tumors of the central nervous system in children and adolescents. Dtsch Arztebl Int. 2011;108:390-397.
Rutkowski S, Bode U, Deinlein F, et al. Treatment of early childhood medulloblastoma by postoperative chemotherapy alone. N Engl J Med. 2005;352:978-986.
Fangusaro J, Bandopadhayay P. Advances in the classification and treatment of pediatric brain tumors. Curr Opin Pediatr. 2021;33:26-32.
Lacour B, Goujon S, Guissou S, et al. Childhood cancer survival in France, 2000-2008. Eur J Cancer Prev. 2014;23:449-457.
Fischer J, Pohl A, Volland R, et al. Complete surgical resection improves outcome in INRG high-risk patients with localized neuroblastoma older than 18 months. BMC Cancer. 2017;17:520.
Berthold F, Ernst A, Hero B, et al. Long-term outcomes of the GPOH NB97 trial for children with high-risk neuroblastoma comparing high-dose chemotherapy with autologous stem cell transplantation and oral chemotherapy as consolidation. Br J Cancer. 2018;119:282-290.
Berthold F, Spix C, Kaatsch P, Lampert F. Incidence, survival, and treatment of localized and metastatic neuroblastoma in Germany 1979-2015. Pediatr Drugs. 2017;19:577-593.
Berthold F, Spix C, Erttmann R, et al. Neuroblastoma screening at 1 year of age: the final results of a controlled trial. JNCI Cancer Spectr. 2021;5:5.
Bölling T, Hardes J, Dirksen U. Management of bone tumours in paediatric oncology. Clin Oncol. 2013;25:19-26.
Koscielniak E, Blank B, Vokuhl C, et al. Long-term clinical outcome and prognostic factors of children and adolescents with localized rhabdomyosarcoma treated on the CWS-2002P protocol. Cancer. 2022;14:899.
Doyen J, Jazmati D, Geismar D, et al. Outcome and patterns of relapse in childhood parameningeal rhabdomyosarcoma treated with proton beam therapy. Int J Radiat Oncol Biol Phys. 2019;105:1043-1054.
Pui CH, Yang JJ, Hunger SP, et al. Childhood acute lymphoblastic leukemia: progress through collaboration. J Clin Oncol. 2015;33:2938-2948.
Karim-Kos HE, Hackl M, Mann G, et al. Trends in incidence, survival and mortality of childhood and adolescent cancer in Austria, 1994-2011. Cancer Epidemiol. 2016;42:72-81.
Desandes E, Berger C, Tron I, et al. Childhood cancer survival in France, 1990-1999. Eur J Cancer. 2008;44:205-215.
Gatta G, Zigon G, Capocaccia R, et al. Survival of European children and young adults with cancer diagnosed 1995-2002. Eur J Cancer. 2009;45:992-1005.
Pritchard-Jones K, Hargrave D. Declining childhood and adolescent cancer mortality: great progress but still much to be done. Cancer. 2014;120:2388-2391.
Schmiegelow K, Forestier E, Hellebostad M, et al. Long-term results of NOPHO ALL-92 and ALL-2000 studies of childhood acute lymphoblastic leukemia. Leukemia. 2010;24:345-354.
Mogensen H, Modig K, Tettamanti G, Erdmann F, Heyman M, Feychting M. Survival after childhood cancer-social inequalities in high-income countries. Front Oncol. 2018;8:485.
Bonaventure A, Harewood R, Stiller CA, et al. Worldwide comparison of survival from childhood leukaemia for 1995-2009, by subtype, age, and sex (CONCORD-2): a population-based study of individual data for 89 828 children from 198 registries in 53 countries. Lancet Haematol. 2017;4:e202-e217.
Schulpen M, Visser O, Reedijk AMJ, et al. Significant improvement in survival of advanced stage childhood and young adolescent cancer in The Netherlands since the 1990s. Eur J Cancer. 2021;157:81-93.
Wellbrock M, Zeeb H, Spix C, Grabow D, Borkhardt A, Erdmann F. Survival in children below the age of 15 years with leukemia: temporal patterns in eastern and Western Germany since German reunification. HemaSphere. 2022;6:e755.
Paapsi K, Baburin A, Mikkel S, Magi M, Saks K, Innos K. Childhood cancer incidence and survival trends in Estonia (1970-2016): a nationwide population-based study. BMC Cancer. 2020;20:30.
Helligsoe ASL, Kenborg L, Henriksen LT, Udupi A, Hasle H, Winther JF. Incidence and survival of childhood central nervous system tumors in Denmark, 1997-2019. Cancer Med. 2022;11:245-256.
Gnekow AK, Kandels D, Pietsch T, et al. Doubling recruitment of pediatric low-grade glioma within two decades does not change outcome - report from the German LGG studies. Klin Padiatr. 2021;233:107-122.
Lightfoot TJ, Johnston WT, Simpson J, et al. Survival from childhood acute lymphoblastic leukaemia: the impact of social inequality in the United Kingdom. Eur J Cancer. 2012;48:263-269.
Miranda-Filho A, Bray F, Charvat H, Rajaraman S, Soerjomataram I. The world cancer patient population (WCPP): an updated standard for international comparisons of population-based survival. Cancer Epidemiol. 2020;69:101802.